Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

Madueke I, Abern MR.

Oncology (Williston Park). 2019 Jun 19;33(6):235, 237-8, 242. No abstract available.

2.

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

PMID:
24071481
3.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

4.

Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.

Perlis N, Sayyid R, Evans A, Van Der Kwast T, Toi A, Finelli A, Kulkarni G, Hamilton R, Zlotta AR, Trachtenberg J, Ghai S, Fleshner NE.

J Urol. 2017 Jan;197(1):75-83. doi: 10.1016/j.juro.2016.07.076. Epub 2016 Jul 22.

PMID:
27457260
5.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.

J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26.

PMID:
27569437
6.

Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.

Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS.

J Urol. 2017 Mar;197(3 Pt 1):632-639. doi: 10.1016/j.juro.2016.09.070. Epub 2016 Sep 14.

7.

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB.

J Urol. 2013 Oct;190(4):1218-22. doi: 10.1016/j.juro.2013.04.071. Epub 2013 Apr 30.

8.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.

PMID:
28753811
9.

Appropriateness Criteria for Active Surveillance of Prostate Cancer.

Cher ML, Dhir A, Auffenberg GB, Linsell S, Gao Y, Rosenberg B, Jafri SM, Klotz L, Miller DC, Ghani KR, Bernstein SJ, Montie JE, Lane BR; Michigan Urological Surgery Improvement Collaborative.

J Urol. 2017 Jan;197(1):67-74. doi: 10.1016/j.juro.2016.07.005. Epub 2016 Jul 14.

PMID:
27422298
10.

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.

Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR.

Eur Urol Oncol. 2018 Oct;1(5):386-394. doi: 10.1016/j.euo.2018.04.018. Epub 2018 May 24.

PMID:
31158077
11.

Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.

Jpn J Clin Oncol. 2013 May;43(5):553-8. doi: 10.1093/jjco/hyt041. Epub 2013 Apr 11.

PMID:
23580758
12.

Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.

Bokhorst LP, Roobol MJ, Bangma CH, van Leenders GJ.

Prostate. 2017 Jul;77(10):1137-1143. doi: 10.1002/pros.23372. Epub 2017 May 24.

PMID:
28543353
13.

Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience.

Bosco C, Cozzi G, Kinsella J, Bianchi R, Acher P, Challacombe B, Popert R, Brown C, George G, Van Hemelrijck M, Cahill D.

Ecancermedicalscience. 2016 Apr 14;10:633. doi: 10.3332/ecancer.2016.633. eCollection 2016.

14.

Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.

Voss J, Pal R, Ahmed S, Hannah M, Jaulim A, Walton T.

BJU Int. 2018 Jun;121(6):863-870. doi: 10.1111/bju.14100. Epub 2018 Jan 17.

15.

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.

BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.

16.

Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.

Jain S, Loblaw A, Vesprini D, Zhang L, Kattan MW, Mamedov A, Jethava V, Sethukavalan P, Yu C, Klotz L.

J Urol. 2015 Jul;194(1):79-84. doi: 10.1016/j.juro.2015.01.102. Epub 2015 Feb 4.

PMID:
25660208
17.

Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance.

Shapiro RH, Johnstone PA.

Urology. 2012 Sep;80(3):661-6. doi: 10.1016/j.urology.2012.06.022. Review.

PMID:
22925240
18.

Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.

Overholser S, Nielsen M, Torkko K, Cwilka D, Weaver B, Shi X, Leach RJ, Hernandez J, Huang T, Thompson IM Jr, Thompson IM 3rd.

J Urol. 2015 Sep;194(3):680-4. doi: 10.1016/j.juro.2015.01.089. Epub 2015 Jan 28.

PMID:
25636657
19.

Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.

Tsang CF, Tsu JH, Lai TC, Wong KW, Ho BS, Ng AT, Ma WK, Yiu MK.

Hong Kong Med J. 2017 Dec;23(6):609-15. doi: 10.12809/hkmj166194. Epub 2017 Oct 13.

20.

Pathological outcomes in men with prostate cancer who are eligible for active surveillance.

Wang SC, Chen CC, Yang CK, Hung SW, Jan YJ, Ou YC.

J Chin Med Assoc. 2018 Apr;81(4):348-351. doi: 10.1016/j.jcma.2017.07.008. Epub 2017 Oct 2.

Supplemental Content

Support Center